infections, but the independent contributions of HCV and HIV to HS are unclear. Magnetic resonance imaging and spectroscopy were used to measure visceral adipose tissue (VAT) and liver fat fraction (LFF) (total lipids/[total lipids 1 water]) in 356 adults: 57 with HCV monoinfection, 70 with HIV/HCV coinfection, 122 with HIV monoinfection, and 107 with neither infection. Participants who were infected with HCV genotype 3 were excluded because of the genotype's reported steatogenic effects. For prevalence estimates, HS was defined as LFF 0.05. We estimated the association of HIV and HCV status with LFF using multivariable linear regression, adjusting for demographics, lifestyle, and metabolic factors including the homeostasis model assessment estimate of insulin resistance (HOMA-IR) and liver fibrosis defined using the aspartate aminotransferase-to-platelet ratio index (APRI). The prevalence of HS was highest in the uninfected (33%) and HIV-monoinfected (28%), followed by the HCV-monoinfected (19%) and HIV/HCV-coinfected (11%) (P 5 0.003 across groups). Compared with uninfected participants-and after adjusting for demographics, lifestyle, and metabolic factors-HIV monoinfection, HCV monoinfection, and HIV/HCV coinfection were associated with 19% (95% confidence interval [CI], 239% to 6%), 38% (95% CI, 255% to 212%), and 42% (95% CI, 259% to 218%) lower LFF, respectively. HCV monoinfection and HIV/HCV coinfection remained strongly associated with lower LFF after further adjusting for APRI, and results were unchanged after excluding subjects with suspected cirrhosis. Among the entire cohort, Hispanic ethnicity, male sex, VAT, and HOMA-IR were independently associated with greater LFF. Conclusion: Contrary to expectations, HIV/HCV-coinfected and HCV-monoinfected adults had significantly less liver fat than uninfected adults, even after adjusting for demographics, lifestyle, metabolic factors, and hepatic fibrosis. Our findings suggest that non-genotype 3 HCV infection may be protective against HS. The mechanisms by which this occurs and the impact of HCV treatment on HS requires further investigation. (HEPATOLOGY 2017;65:853-863) 
H epatic steatosis (HS) is common in individuals chronically infected with hepatitis C virus (HCV) and is independently associated with increased fibrosis progression (1) (2) (3) (4) (5) and development of hepatocellular carcinoma. (6) (7) (8) The reported prevalence of histologic HS ranges from 35% to 81% in HCVmonoinfected persons and 23% to 72% in HIV/HCVcoinfected persons. (5, 9) The high frequency of HS on liver biopsy in patients with HCV, in comparison with the estimated 20%-30% prevalence of HS in the Abbreviations: AIDS, acquired immune deficiency syndrome; ALT, alanine aminotransferase; APRI, aspartate aminotransferase-to-platelet ratio index; ART, antiretroviral therapy; AST, aspartate aminotransferase; BMI, body mass index; CI, confidence interval; FIB-4, fibrosis-4; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HS, hepatic steatosis; HOMA-IR, homeostatic model assessment of insulin resistance; LFF, liver fat fraction; MRS, magnetic resonance spectroscopy; SAT, subcutaneous adipose tissue; VAHH, Study of Visceral Adiposity; HIV, and HCV: Biologic Mediators of Hepatic Steatosis; VAT, visceral adipose tissue; WIHS, Women's Interagency HIV Study.
general population, (10, 11) suggests that HCV-infected patients have an elevated risk of HS. (12) There are several postulated mechanisms by which HCV may lead to HS, including increased intrahepatic triglyceride accumulation (due to viral inhibition of very low density lipoprotein assembly and secretion), decreased fatty acid oxidation, and increased de novo lipogenesis. (13, 14) Indeed, several studies provide compelling evidence for a direct steatogenic effect of HCV genotype 3. (15) (16) (17) However, whether non-genotype 3 HCV affects the risk of HS is unclear, and HS in this group appears to be primarily mediated by metabolic factors. (9, 18) It is difficult to directly compare HS rates from studies conducted among HCV-infected patients with those conducted in HCV-uninfected populations. Variability in the frequency of metabolic comorbidities and other HS risk factors across studies may explain in part the wide range of HS prevalence reported in the literature. In addition, most studies in HCV patients rely on liver biopsy, whereas estimates of HS in the general population are based on noninvasive imaging or serum markers. Only a minority of HCV patients will undergo liver biopsy, and HS is associated with advanced fibrosis in HCV. Therefore, HS may be overestimated in biopsy series if HCV patients with suspected advanced disease are more likely to have a biopsy performed.
Hepatic steatosis is also common in HIV-infected individuals, with a reported prevalence of 13% to 73% depending on the population studied and the imaging technique used for diagnosis. (19) (20) (21) (22) (23) (24) (25) Like HCV, HIV has been postulated to induce HS, either directly through chronic immune activation, increased lipogenesis, and alterations in insulin signaling or indirectly via metabolic abnormalities and antiretroviral therapyinduced steatosis. (26) Although it has been suggested that HIV independently increases the risk of HS, a report from the Multicenter AIDS Cohort Study found a lower risk of CT-measured HS in HIVinfected men compared with HIV-uninfected men. (23) However, this study was unable to evaluate the role of HCV infection, and did not include women.
The objective of the current study was to determine whether HIV and HCV infections are independently associated with HS (measured using magnetic resonance spectroscopy (MRS), which is considered the preferred reference standard for noninvasive measurement of liver fat (27) ) in a representative cohort of men and women and to identify associated risk factors for HS in this population.
Patients and Methods

STUDY DESIGN AND PATIENTS
Between December 2003 and July 2015, 363 adults with and without HIV and HCV infections underwent MRS to measure liver fat fraction (LFF). One hundred thirty-nine women were recruited from the Northern California site of the Women's Interagency HIV Study (WIHS) as part of the MRS Steatosis Substudy. Details of WIHS recruitment, characteristics, and study design have been described elsewhere. (28) Participants of the Study of Visceral Adiposity, HIV, and HCV: Biologic Mediators of Hepatic Steatosis (the VAHH Study), which enrolled men and women without evidence of clinical diabetes and with/without HIV and HCV from clinics and recruitment flyers posted at the San Francisco Veterans Affairs Medical Center, were also included in the study. Of the 224 VAHH and 139 WIHS participants, 356 had MRS data available and were included in the study. Potential WIHS MRS Steatosis Substudy and VAHH participants were excluded if they were pregnant or 3 months postpartum (women only); received medications associated with steatosis, including corticosteroids, amiodarone, methotrexate, tamoxifen, and estrogen; were receiving anti-HCV therapy; had detectable hepatitis B surface antigen; had a body mass index (BMI) > 35 kg/m 2 ; weighed > 300 pounds; had metal objects in their bodies; had evidence of severe renal insufficiency (defined as estimated glomerular filtration rate <30 mL/min); had evidence of decompensated cirrhosis; or had evidence of chronic liver disease due to primary biliary cirrhosis, hemochromatosis, or autoimmune hepatitis. For this study, seven participants with genotype 3 HCV were excluded because of the known steatogenic effects of this genotype. There were 10 subjects with unknown genotype (two with HCV monoinfection and eight with HIV/HCV coinfection), and they were considered to have non-genotype 3 infection. The study was approved by an Institutional Review Board, and all participants signed informed consent.
HEPATIC STEATOSIS AND ADIPOSE TISSUE MEASUREMENTS
From December 2003 through February 2010, MR imaging was conducted on a 1.5T whole body clinical scanner (General Electric Healthcare, Waukesha, WI).
Beginning in March 2010, MR imaging was performed on a 3T whole body scanner (General Electric Healthcare). Data collected from the 1.5T scanner were calibrated to values collected from the 3T scanner using in-house values correcting for field-dependent relaxation times. MRS was acquired from an 8-cm 3 voxel similarly to prior reports, with a 128 (1.5T) or 64 (3T) acquisition time series of spectra. (29) Spectra were automatically corrected for phase, frequency, motion, and T2 relaxation time. (30) (31) (32) Quality was visually confirmed by an MR spectroscopist with over 20 years of experience. We calculated LFF from the corrected MRS measures of CH 2 and CH 3 lipids and of water as the total lipids/(total lipids 1 water). The LFF was then multiplied by 100 and expressed as a percentage.
Visceral adipose tissue (VAT) and abdominal subcutaneous adipose tissue (SAT) volumes were semiautomatically generated based on either a water-suppressed gradient dual echo or an iterative decomposition and echo asymmetry with least-squares estimation sequence (breathheld, slice thickness 5 10 mm). Slices were located at the discs between lumbar vertebrae L2-3, L3-4, and L4-5. VAT and SAT image masks were manually created by an experienced user, followed by a semiautomatic threshold-based contour mapping algorithm for total VAT and SAT area. Slices were averaged to generate a total VAT and abdominal SAT volume per patient.
COVARIATES
HIV infection was defined by documentation of a positive HIV enzyme immunoassay confirmed with western blot, and chronic HCV infection was defined as serum HCV antibody and HCV RNA positive. Alcohol consumption was self-reported and was categorized as none, light (>0-7 drinks/wk), moderate (7-12 drinks/ wk), or heavy (>12 drinks/wk). Additional candidate covariates, including race, ethnicity, history of injection drug use, smoking, and marijuana use were obtained through self-reporting. Race was categorized as white (including white Hispanic), African American (including African American Hispanic), or other, and ethnicity was categorized as Hispanic or non-Hispanic. Diabetes was defined as any one of the following: ever used a diabetic medication, fasting glucose 126 mg/dL, or hemoglobin A1c 6.5%. The homeostatic model assessment of insulin resistance (HOMA-IR) was calculated using 8-hour fasting insulin and glucose values. Liver fibrosis was estimated using the aspartate aminotransferase (AST)-to-platelet ratio index (APRI), which incorporates AST and platelets, and the FIB-4 score, which is calculated using the variables age, AST, platelets, and alanine aminotransferase (ALT). (33, 34) Probable cirrhosis was defined as APRI > 2 or FIB-4 > 3.25. For HS prevalence estimates, total lipids/(total lipids 1 water) 0.05 was considered HS. (29) 
STATISTICAL ANALYSIS
We compared demographic and clinical characteristics by disease category (HIV-monoinfected, HCVmonoinfected, HIV/HCV-coinfected, and uninfected controls) using an analysis of variance model or KruskalWallis test for continuous variables and the chi-squared test or Fisher's exact test for categorical variables, where appropriate. We compared levels of LFF by disease category using least-squared means and their confidence intervals after adjusting for age, race, ethnicity, and BMI. Because it is possible that MRS might underestimate the LFF in the setting of fibrosis, (35) Spearman correlations were used to examine the association between APRI and LFF, stratified by infection category. We used both unadjusted and multivariable adjusted linear regression models to compare differences in LFF by disease category while controlling for demographics, lifestyle, and metabolic factors, as well as APRI, FIB-4, or suspected cirrhosis. We also performed a sensitivity analysis excluding subjects with suspected cirrhosis. Finally, we performed additional analyses to identify factors associated with LFF stratified in the entire cohort and by HIV and chronic HCV status, adjusting for HIVrelated factors and HCV-related factors as appropriate.
A robust regression model with Huber's Mestimation was used to alleviate the impact of influential cases. LFF was found to have a right-skewed distribution and therefore was log-transformed to normalize its distribution. The regression coefficients and their confidence intervals were exponentiated to calculate percentage differences attributable to each risk factor. In models with missing cases, multiple imputation with the Markov chain Monte Carlo method was used to impute missing covariates, with 20 repetitions. All analyses were performed using SAS software, version 9.4 (SAS Institute Inc., Cary, NC).
Results
CHARACTERISTICS OF PARTICIPANTS
A total of 356 participants were included: 122 with HIV monoinfection, 57 with HCV monoinfection, 70 with HIV/HCV coinfection, and 107 with neither infection. There were several notable demographic and metabolic differences comparing patients by HIV and HCV status ( Table 1 ). The HCV-monoinfected and the HIV/ HCV-uninfected groups were predominantly male, whereas the majority of HIV/HCV-coinfected patients were female. The HCV-infected participants were older and were more likely to have a history of injection drug use. The HCV-monoinfected and the HIV/HCV-uninfected groups were more likely to drink alcohol heavily than the HIV-infected patients. Most of the HIV/ HCV-coinfected and the HIV/HCV-uninfected patients were African American or Hispanic, whereas the majority of HIV-monoinfected and HCVmonoinfected patients were white. The HIV/HCVcoinfected patients also had the highest HOMA-IR values and were more likely to be diagnosed with diabetes; however, they had on average the lowest BMI, least amount of VAT, and lowest LDL levels. As expected, the HCV-infected patients had the highest APRI and FIB-4 scores and were more likely to have cirrhosis.
Among the 127 HCV-infected patients (with and without HIV), most were infected with genotype 1; 14 patients had genotype 2, and five patients had genotype 4. The majority of the HIV-infected group was on highly active antiretroviral therapy (78% of HIVmonoinfected patients and 83% of HIV/HCV-coinfected patients). Compared with the HIV/HCV-coinfected group, the HIV-monoinfected group had a higher proportion with undetectable HIV RNA (74% versus 54%, P 5 0.006), higher CD4 counts (median 579 versus 466, P 5 0.001), and a lower proportion with a history of clinical acquired immune deficiency syndrome (AIDS) (37% versus 56%, P 5 0.011)
HEPATIC STEATOSIS BY HIV AND HCV STATUS
The prevalence of HS was highest in the HIV/HCVuninfected (33%) and HIV-monoinfected (28%) groups, followed by the HCV-monoinfected (19%) and HIV/ HCV-coinfected (11%) groups (P 5 0.003 across groups). After adjusting for age, race, ethnicity, and BMI, the mean LFF was also highest in the HIV/ HCV-uninfected (3.1%; 95% confidence interval [CI], 2.4% to 4.1%), followed by the HIV-monoinfected (2.8%; 95% CI, 2.2% to 3.5%), HIV/HCV-coinfected (2.2%; 95% CI 1.6% to 3.0%), and HCV-monoinfected (2.1%; 95% CI, 1.6% to 3.0%) groups (Fig. 1) .
After multivariable adjustment for demographics, lifestyle, and metabolic factors, the HIV-monoinfected participants had 19% lower LFF than the HIV/HCVuninfected, but the difference was not statistically significant (95% CI, -39% to 6%, P 5 0.12) ( Table 2 ). In contrast, even after adjusting for these factors, HCVmonoinfected and HIV/HCV-coinfected participants had 38% (95% CI, 255% to 212%, P 5 0.006) and 42% (95% CI, 259% to 218%, P 5 0.002) lower LFF, respectively, compared with the HIV/HCV-uninfected. Because MRS might underestimate the LFF in the setting of fibrosis, (35) we evaluated the correlation of liver fibrosis (as measured by APRI) with LFF, stratified by infection category. We found that in each group, increasing LFF was associated with increasing APRI (Fig. 2) . Notably, even though the HCVinfected participants had the highest APRI values, at any given APRI, the average LFF was lowest in the HCV-infected groups. This is reinforced in our multivariable models-after adjusting for APRI, the association of HCV with lower LFF was strengthened (Table  2) . We also performed analyses in which APRI, FIB4, and cirrhosis were tested in the multivariable models, and the results remained the same: HIV monoinfection was associated with lower LFF, but this was not statistically significant, whereas HCV monoinfection and HIV/HCV coinfection were independently associated with significantly lower LFF (APRI results shown in Table 2 ). Finally, we performed a sensitivity analysis excluding individuals with suspected cirrhosis, and the multivariable results were unchanged (Table 2) .
FACTORS ASSOCIATED WITH STEATOSIS
Because HIV-and HCV-infected patients had lower LFF, even after multivariable adjustment, we performed additional analyses to identify factors associated with LFF in the entire cohort and stratified by infection status. Among the entire cohort and after excluding participants with suspected cirrhosis, Hispanic ethnicity, male sex, VAT, and HOMA-IR were each independently associated with higher LFF: 32% higher for Hispanics (95% CI, 0% to 74%; P 5 0.05), 41% higher for men (95% CI, 5% to 89%; P 5 0.024), 83% higher per doubling of VAT (95% CI, 58% to 111%; P < 0.001), and 34% higher per doubling of HOMA-IR (95% CI, 22% to 47%; P < 0.001).
Among HIV-infected persons, several factors were associated with higher LFF in unadjusted analysis: male sex, BMI, waist circumference, VAT, abdominal SAT, HOMA-IR, ALT, and albumin (Table 3) . By contrast, factors associated with lower LFF in unadjusted analysis included HIV/HCV coinfection, African American race, cigarette smoking, and current marijuana use. On multivariable analysis, VAT remained significantly associated with higher LFF (53% per doubling; 95% CI, 31% to 79%; P < 0.001), as did HOMA-IR (17% per doubling; 95% CI, 7% to 29%; P 5 0.001), and serum albumin (5% per 0.1 g/dL increase; 95% CI, 1% to 8%; P 5 0.005), whereas current marijuana use was associated with lower LFF (220%; 95% CI, 236% to 21%; P 5 0.039). Although HIV-related factors, including HIV RNA level, CD4 count, current highly active antiretroviral therapy, history of AIDS, and years on antiretroviral therapy (ART) showed little association with LFF on unadjusted analysis, after multivariable adjustment we found that higher HIV RNA was associated with higher LFF (5% increase per doubling of HIV RNA; 95% CI, 1% to 10%; P 5 0.017) ( Table 3) . Results remained consistent after further adjusting for APRI and after excluding participants with cirrhosis (Supporting Table S1 ). Among HCV-infected patients, LFF was primarily mediated by metabolic factors (Table 4) . On unadjusted analysis, greater BMI, waist circumference, VAT, abdominal SAT, leg fat, and HOMA-IR were each associated with higher LFF. HCV RNA and history of HCV treatment showed little association with LFF. On unadjusted analysis, greater APRI was associated with higher LFF (18%; 95% CI, 6% to 33%; P 5 0.004), but after multivariable adjustment this association weakened and was no longer statistically significant. On multivariable analysis, the only factors that remained significantly associated with LFF were VAT (49%; 95% CI, 26% to 76%, P < 0.001) and ALT (18%; 95% CI, 3% to 36%; P 5 0.017). The results were qualitatively similar on sensitivity analysis excluding patients with presumed cirrhosis (Supporting Table S2 ).
Discussion
In this ethnically diverse study of 356 adults with HIV or HCV monoinfection, HIV/HCV coinfection, and neither infection, we found that chronic infection with HIV and/or HCV infection was not associated with greater HS. Rather, HCV-infected participants (with and without HIV) had significantly lower MRS-measured LFF and HIV-monoinfected participants had slightly lower LFF than HIV/HCV-uninfected participants. Our finding of a lower LFF among those with HCV infection was unexpected and persisted despite adjusting for demographics, lifestyle, adipose tissue, and metabolic factors. Furthermore, this relationship remained significant after additional adjustment for hepatic fibrosis and after exclusion of participants with suspected cirrhosis, suggesting that HCV impacts liver fat storage independent of fibrosis. Our results challenge the widely held perception that non-genotype 3 HCV is associated with greater HS.
Previous studies have shown a relatively high prevalence of HS among HIV-monoinfected individuals (19) (20) (21) 24, 25) but did not include an uninfected comparison group. These estimated prevalence rates vary depending on the modality used to measure HS, with reports of 31% and 54% prevalence using ultrasound, 37% using noncontrast CT, and 40% and 48% using transient elastography with controlled attenuation parameter. (19) (20) (21) 25, 36) Another study of 62 HIV-monoinfected patients on ART found that 73% had HS on liver biopsy. (24) These high HS prevalence estimates have led many to hypothesize that HIV infection is an independent risk factor for HS. Indeed, HIV could lead to HS through a variety of mechanisms, including chronic immune activation, direct interaction with the sterol regulatory element binding protein (SREBP-1), which stimulates lipogenesis, and alterations in insulin signaling. (37) Additionally, ART, especially the nucleoside reverse transcriptase inhibitors, have been postulated to cause steatosis via inhibition of mitochondrial polymerase c, and protease inhibitors by inducing hepatic overexpression of SREBP-1, (26, 38) although their effects may be more modest with the use of newer drugs within these classes. Finally, HIV infection and ART are associated with metabolic perturbations that have been strongly linked to HS. (39) Our findings corroborate the results of another study of 719 men in the Multicenter AIDS Cohort Study, in which HIV was not a risk factor for HS as determined by noncontrast CT, and in fact was associated with a lower prevalence of HS. (23) Our study is now the second (5, 25) However, HIV viremia despite ART has been associated with increased gut microbial translocation and systemic inflammation, both of which have been implicated in HS pathogenesis. (40, 41) Future evaluation of the relationship between HIVrelated microbial translocation and HS is warranted.
Hepatic steatosis is common in the setting of HCV and is associated with worsened liver disease progression.
(1-5) The higher reported prevalence of histologic HS in HCV-infected populations as compared with the general population has resulted in the belief that HS is more prevalent in HCV-infected individuals than in those without HCV. (12) However, while genotype 3 HCV can directly cause HS, (15) (16) (17) HS in the setting of non-genotype 3 HCV infection is primarily mediated by metabolic factors. (9, 18) We, too, found a strong association between metabolic factors, particularly VAT, and HS in our entire cohort as well as in the HCV-infected subgroup. Although the prevalence of HS in our HCV-infected group was in the lower range reported in HCV-positive populations (19% in HCV-monoinfected patients and 11% in HIV/HCVcoinfected patients), it is important to note the heterogeneity in patient characteristics across these studies. In addition, histologic studies of HS and HCV may overestimate HS if there is selection bias in referral for biopsy, because both elevated aminotransferases and advanced fibrosis are associated with increased HS.
The most surprising finding in our study was the inverse association of HCV with liver fat. This study directly compared HS in a cohort of participants with HIV or HCV monoinfection, HIV/HCV coinfection, and neither infection. A few prospective studies have evaluated risk factors for HS in HIV-infected individuals with and without HCV coinfection, each using different noninvasive imaging modalities to assess HS, and they did not find a difference in HS by HCV status. (21, 25, 42) Similarly, when we restricted our analysis to HIV-infected individuals, HCV was not independently associated with HS. However, in the entire cohort analysis, both HCV monoinfection and HIV/HCV coinfection were clearly associated with lower HS.
The reasons for our unexpected finding of lower HS in the HCV-infected groups compared with the HIV/ HCV-uninfected participants are unclear. As patients with nonalcoholic steatohepatitis progress to cirrhosis, HS can regress histologically, resulting in "burned out" cirrhosis. (43) Because our study was cross-sectional and the HCV-infected subjects were more likely to have cirrhosis, we considered that this may explain their lower amounts of HS. However, the negative association of HCV with HS persisted even after excluding individuals with suspected cirrhosis. We also considered whether the accuracy of MRS-measured HS may be altered by HCV-related fibrosis or inflammation. We demonstrated previously that MRS and histologic steatosis were strongly associated in 42 HIV/HCVcoinfected men and women, including 20 women who also participated in our current study. (44) Others have shown that HCV, hepatic inflammation, and fibrosis do not directly influence the accuracy of MRS in detecting HS. (35, 45) However, some have suggested that as fibrosis progresses and hepatocytes are replaced by fibrous tissue, MRS may underestimate the percentage of steatotic hepatocytes. (35) We therefore included estimated fibrosis stage in our analysis, and the relationship between HCV and HS did not change. Moreover, HS and liver fibrosis were positively correlated in our cohort. Thus, the higher prevalence of advanced fibrosis and cirrhosis among the HCVinfected individuals in the cohort does not explain the apparent protective effect of HCV against HS.
Although there were differences in the characteristics of the cohort by HIV and HCV disease category, it is notable that the relationship between HCV and HS was not attenuated even after adjusting for demographics, lifestyle, and metabolic factors. It is possible that unmeasured confounders, such as healthier behavior, more frequent physician visits, and more aggressive management of medical comorbidities would preferentially reduce HS in those with known HCV. It is also possible that HCV itself is protective against HS, although the crosssectional nature of this study limits our ability to demonstrate this. C-reactive protein levels are substantially reduced in the setting of chronic HCV, due in part to an attenuated response to interleukin (IL)-6 in the presence of HCV. (46, 47) Both hepatic and serum levels of IL-6 are elevated in patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, (48, 49) suggesting a role of IL-6 in the pathogenesis of HS. It is possible that HCV blunts the hepatic response to IL-6 thereby protecting against HS. Future studies evaluating the inflammatory mechanisms of HS in the setting of HCV will help elucidate these relationships. In addition, prospective studies are needed to clarify the association between HCV and HS risk. This is particularly important because although successful HCV treatment can reduce HS in genotype 3 HCV, HCV cure has not been shown to improve HS in non-genotype 3 HCV. (16, 50) As more patients with HCV achieve sustained virologic response with newer HCV antivirals, long-term follow-up of HS in this group may be warranted.
The major limitations of our study include the crosssectional design and heterogeneity of demographic and clinical characteristics between the infection subgroups. Although we adjusted for many factors in our analysis, there are likely differences by HIV and HCV status in other nonassessed parameters for which we could not control. Therefore, our findings must be interpreted in light of this potential bias. Lack of histology to assess HS is another major limitation. However, it would be infeasible to perform a biopsy study in this cohort, which included HIV-monoinfected and HIV/HCV-uninfected controls without indication for liver biopsy. In addition, our study avoids the selection bias inherent in liver biopsies. Finally, two field strengths were used to acquire MRS liver fat measures. We corrected for this but cannot exclude the possibility of minor remaining field effects on LFF. Study strengths include the use of MRS, the reference standard for noninvasive assessment of HS, extensive characterization of metabolic risk factors and direct measures of visceral adiposity, and the inclusion of HIVand HCV-uninfected controls.
In conclusion, we found significantly less HS in HCVmonoinfected and HIV/HCV-coinfected subjects as compared to HIV/HCV-uninfected participants despite adjusting for multiple possible confounders. As expected, visceral adiposity and insulin resistance were strongly associated with greater HS in the cohort. Further research is needed to investigate potential mechanisms by which non-genotype 3 HCV may alter the risk of HS and to evaluate the possible impact of HCV eradication on HS.
